$-0.09
(Market cap
$38 Mln
Revenue (TTM)
$15 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-53 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
50.52
-
EV/EBITDA
-0.1
-
Debt to Equity
-0.2
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
29,521,800
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Codex DNA Inc (DNAY)
| 59.2 | -3.0 | 69.0 | -77.0 | -- | -- | -- |
|
BSE Sensex*
| -12.6 | -4.3 | -4.6 | -10.3 | 5.7 | 7.3 | 10.7 |
|
Company
|
2022
|
|---|---|
|
Codex DNA Inc (DNAY)
| -88.9 |
|
BSE Sensex
| 4.4 |
|
BSE Sensex
| 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Codex DNA Inc (DNAY)
|
1.9 | 38.4 | 15.4 | -52.8 | -352.0 | -- | -- | 0.7 |
| 91.3 | 158,626.9 | 45,134.0 | 6,276.0 | 15.4 | 12.2 | 25.5 | 3.0 | |
| 49.0 | 72,608.5 | 20,615.0 | 3,553.0 | 19.9 | 14.5 | 20.4 | 2.7 | |
| 188.4 | 132,098.3 | 24,778.0 | 3,689.0 | 18.7 | 7.1 | 36.2 | 2.4 | |
| 87.5 | 49,495.8 | 6,303.5 | 1,092.8 | 12.7 | 10.6 | 46.5 | 4.9 | |
| 578.9 | 44,344.9 | 4,446.1 | 1,095.2 | 23.5 | 70.3 | 41.3 | 28.5 | |
| 426.6 | 149,478.0 | 10,582.1 | 2,979.1 | 22.4 | 17.2 | 51.3 | 8.6 | |
| 82.0 | 105,188.7 | 36,364.0 | 4,800.0 | 13.3 | 19.6 | 22 | 1.9 | |
| 314.0 | 115,472.1 | 25,270.0 | 3,337.0 | 18.5 | 15.1 | 34.9 | 4.9 | |
| 494.1 | 179,132.7 | 45,197.0 | 6,859.0 | 19.2 | 13.3 | 26.5 | 3.4 |
Shareholding Pattern
View DetailsAbout Codex DNA Inc (DNAY)
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp... system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California. Read more
-
Pres, CEO & Director
Dr. Todd R. Nelson MBA, Ph.D.
-
Pres, CEO & Director
Dr. Todd R. Nelson MBA, Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Codex DNA Inc (DNAY)
What is the current share price of Codex DNA Inc (DNAY) Today?
The share price of Codex DNA Inc (DNAY) is $1.91 (NASDAQ) as of 08-Mar-2023 09:30 EDT. Codex DNA Inc (DNAY) has given a return of -77.04% in the last 1 years.
What is the current PB & PE ratio of Codex DNA Inc (DNAY)?
Since, TTM earnings of Codex DNA Inc (DNAY) is negative, P/E ratio is not available.
The P/B ratio of Codex DNA Inc (DNAY) is 0.65 times as on 08-Mar-2023, a 80 discount to its peers’ median range of 3.26 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Codex DNA Inc (DNAY)?
The 52-week high and low of Codex DNA Inc (DNAY) are Rs -- and Rs -- as of 10-Jun-2026.
What is the market cap of Codex DNA Inc (DNAY)?
Codex DNA Inc (DNAY) has a market capitalisation of $ 38 Mln as on 08-Mar-2023. As per SEBI classification, it is a company.
Should I invest in Codex DNA Inc (DNAY)?
Before investing in Codex DNA Inc (DNAY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.